Evolus, Inc. (NASDAQ:EOLS) CFO Sells $119,286.96 in Stock

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver sold 8,996 shares of Evolus stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $119,286.96. Following the transaction, the chief financial officer now owns 173,583 shares of the company’s stock, valued at $2,301,710.58. This represents a 4.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Sandra Beaver also recently made the following trade(s):

• On Monday, December 23rd, Sandra Beaver sold 1,586 shares of Evolus stock. The stock was sold at an average price of $10.85, for a total value of $17,208.10.

Evolus Stock Performance

NASDAQ:EOLS opened at $13.03 on Friday. The stock has a market cap of $828.54 million, a P/E ratio of -14.32 and a beta of 1.28. The stock has a 50 day simple moving average of $13.42 and a 200 day simple moving average of $13.88. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a 1-year low of $9.25 and a 1-year high of $17.82.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on EOLS. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Evolus in a research note on Wednesday, March 5th. Barclays lifted their target price on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Evolus in a research note on Wednesday, March 5th.

Institutional Trading of Evolus

Several hedge funds have recently added to or reduced their stakes in EOLS. KBC Group NV acquired a new stake in Evolus during the 4th quarter worth approximately $49,000. IFP Advisors Inc raised its holdings in Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after acquiring an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Evolus in the 4th quarter valued at $106,000. Rafferty Asset Management LLC acquired a new position in Evolus in the 4th quarter valued at $115,000. Finally, Quantbot Technologies LP acquired a new position in Evolus in the 4th quarter valued at $118,000. 90.69% of the stock is owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.